CLINICAL TRIAL

Bilateral Motor Priming + Task Specific Training (BMP + TST) for Paresis

Recruiting · 18+ · All Sexes · Chicago, IL

This study is evaluating whether a combination of two types of therapy may help improve the use of the arm following a stroke.

See full description

About the trial for Paresis

Eligible Conditions
Stroke · Paresis

Treatment Groups

This trial involves 2 different treatments. Bilateral Motor Priming + Task Specific Training (BMP + TST) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Bilateral Motor Priming + Task Specific Training (BMP + TST)
BEHAVIORAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Control Priming + TST (CP + TST)
BEHAVIORAL

Eligibility

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
An FMUE score of 23 to 38 falls within the "average" range. show original
The person had evidence of a stroke that occurred at least 6 months before enrolling in the study. show original
On the Modified Ashworth Scale, a score of 0 means the person can move their wrist freely in all directions show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Change in baseline Fugl Myer Score at follow-up (8 weeks after treatment ends)
Screening: ~3 weeks
Treatment: Varies
Reporting: Change in baseline Fugl Myer Score at follow-up (8 weeks after treatment ends)
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Change in baseline Fugl Myer Score at follow-up (8 weeks after treatment ends).
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Bilateral Motor Priming + Task Specific Training (BMP + TST) will improve 1 primary outcome in patients with Paresis. Measurement will happen over the course of Change in baseline Fugl Myer Score at follow-up (8 weeks after treatment ends).

Fugl Myer Test of Upper Extremity Function
CHANGE IN BASELINE FUGL MYER SCORE AT FOLLOW-UP (8 WEEKS AFTER TREATMENT ENDS)
Examines upper extremity impairment looking at synergy and isolated movement
CHANGE IN BASELINE FUGL MYER SCORE AT FOLLOW-UP (8 WEEKS AFTER TREATMENT ENDS)

Who is running the study

Principal Investigator
D. C.
Prof. Daniel Corcos, Professor, Department of Physical Therapy and Human Movement Sciences
Northwestern University

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of paresis?

Paresis appears mainly in elderly persons, and presents with symptoms such as weakness, tremor, stiffness of the hands and feet, dysphagia, gait incoordination, dysphoric facial expression and facial paralysis. It can be caused by paralysis or paralysis, which can be classified by the affected limbs, with hemifacial paralysis occurring on the right side and peripheral paraparesis on the left side. The cause may be lesions on the spinal nerves or plexus or cerebral cortex as well as peripheral nervous system involvement. Paresis can also be caused by metabolic disturbance (hyperglycemia, hyperlipidemia etc.) and hyperammonemia. Finally, paresis can be congenital and not related to pathology.

Anonymous Patient Answer

Can paresis be cured?

It must be stressed that the treatment of dystonia is primarily symptomatic and is only meaningful in combination with other therapeutic strategies. In some patients it is possible to relieve some symptoms of dystonia or the disability they cause while improving the quality of life.

Anonymous Patient Answer

What is paresis?

Paresis refers to weakness of several limbs, caused by degeneration of motor nerves in the peripheral nervous system. The severity of paresis has to be interpreted on a case-by-case basis. For purposes of prognosis and treatment evaluation, the patient's clinical parameters are the most reliable information; the presence of atelectasis, anosmia, weight loss, muscle wasting and paresthesias are less specific criteria, and only moderate agreement was achieved between the different parameters.

Anonymous Patient Answer

How many people get paresis a year in the United States?

Paresis is diagnosed in more than 8 million Americans each year. There is very little discrepancy between the reported incidence of paresis in children and the estimates of epidemiology based on the analysis of data from medical records.

Anonymous Patient Answer

What are common treatments for paresis?

Paresis tends to be treated with therapies of which only a few remain in current use. Treatments and medications for paresis include medication, surgery, or medical treatment. Surgical treatment can include a surgical procedure to make repairs to an injured nerve or nerves, or nerve grafting.\n

Anonymous Patient Answer

What causes paresis?

Paralysis of a muscle typically happens because of a problem in the nerve supply, and not from problems in the muscle itself. But in all causes of paresis, problems in the nerves can lead to paralysis. The pattern of paralysis and the ways in which paralysis affects the strength of a joint depend on which nerves are involved. The most simple way of figuring out which nerves a clinician should test is to ask which muscles are involved. Sometimes people just mention their main problem. If that is no good then it helps to ask for an elaborate history and examination, and can help determine which nerves are involved.

Anonymous Patient Answer

Have there been any new discoveries for treating paresis?

A significant number of drugs have been tested for the treatment of paresis for more than 25 years. A recent study showed that anti-Parkinson drugs have been used in order to treat Parkinson's disease and may prove effective. There is a growing body of knowledge about the role of iron in the development of paresis in animals and in humans. There is no consensus regarding a treatment protocol and the role for chelation therapy in the treatment of paresis is still to be determined. Further research might also clarify the role of iron in paresis and the usefulness of chelation therapy.

Anonymous Patient Answer

How serious can paresis be?

If the diagnosis of spinal or supraspinal paresis is poorly made in a child at the emergency department, this type of paresis is of serious prognostic importance. There has not been a detailed clinical, electrophysiological, or radiologic study of this condition to date.

Anonymous Patient Answer

Who should consider clinical trials for paresis?

Clinical trials for paresis should be run on an unrestricted population, which is why the need to provide adequate support and information about clinical trials for patients with paresis should be mandatory.

Anonymous Patient Answer

Have there been other clinical trials involving bilateral motor priming + task specific training (bmp + tst)?

At this time there have not been any other clinical trials or research articles with Sibo. In fact, most of the literature on Sibo is from non-clinical, non-blinded, non-randomized clinical research. Most research has been conducted in a single centre, and few studies have been extended beyond 12 weeks. To address these and other research problems, the European Consensus group has made a recent request for these research problems to be highlighted in an international consultation document, the 'Clinical Trials Needed in Lupus' (CTnl), to provide guidance to those investigating Sibo, and more broadly for those investigating brain and spinal cord pathology in rheumatic diseases.

Anonymous Patient Answer

What is the average age someone gets paresis?

Findings from a recent study confirms the data reported by Lass and Trompenburg published in 1975. This means, for instance, people over 75 years of age suffer from severe forms of muscular atrophy similar to the most severe forms of amyotrophic lateral sclerosis seen in younger individuals. Younger patients are usually less severely affected. On the other hand, children under 10 have a more severe muscular atrophy than older children. Children born after 1960, and to a lesser extent those born after 1940, are the least severely affected by mild forms of muscular atrophy.

Anonymous Patient Answer

Does paresis run in families?

Our observation that autosomal dominant paresis occurred in many of our kindreds in contrast to its more classical description as only occurring in families with multiple members with the same disease supports the conclusions of other investigators that inheritance of this progressive neurological condition is multifaceted and warrants further investigation.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Paresis by sharing your contact details with the study coordinator.